Recruiting

Testing an antifungal drug to treat chronic hepatitis B infection

Plain-English translation of NCT06295328 on ClinicalTrials.gov ↗ · Source last updated February 2025 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This clinical trial is testing whether —a medication normally used to treat fungal infections—might help treat chronic hepatitis B. Researchers believe this medication could reduce the virus's ability to replicate in liver cells, potentially allowing your immune system to fight the infection more effectively. You would receive either the medication or a placebo, sometimes combined with an existing hepatitis B treatment.

Currently, there is no cure for chronic hepatitis B. The virus hides in liver cells in a form that standard antiviral drugs cannot easily eliminate. This trial is exploring whether this medication could suppress the virus's replication machinery, giving your body a better chance to clear the infection.

Do you qualify?

You likely qualify if…

you are between 18 and 60 years old
you have been diagnosed with chronic hepatitis B for at least 6 months
your liver function tests are normal and show no signs of cirrhosis or damage
you are either not taking any antiviral medications, or you have been taking tenofovir (one specific hepatitis B medication) for more than 6 months
your body mass index is between 17.0 and 35.0
you are willing to use contraception if you are of childbearing age

You likely don't qualify if…

you have cirrhosis or advanced liver disease
you have another liver infection (hepatitis C, D, E) or HIV
you have kidney problems with low kidney function
you have a history of psoriasis or lupus
you are taking medications that interact with terbinafine or affect how your liver processes it

What participation looks like

You would take a daily oral tablet (either the medication or a placebo) for the duration of the study. The trial involves multiple visits to the research center for blood tests, liver function assessments, and scans to measure liver stiffness. Depending on which group you are in, you may receive the medication alone or in addition to your current hepatitis B treatment. The study is designed to be relatively short and focused on safety and whether the medication affects how much virus is in your blood.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(1 site)

Netherlands

Amsterdam UMC, Amsterdam, North Holland

Key details

Phase

Safety & dosing / Early efficacy

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Enrollment target

~36 participants

Started

April 2022

Primary completion

April 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 60 Years

Last updated on clinicaltrials.gov in February 2025.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

U. Beuers, Prof. Dr.

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

View full record on ClinicalTrials.gov